Cargando…
Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate
Traditional eye drops used for topically administering drugs have poor ocular bioavailability due to the biological barriers of the eye. There is an interest to design and develop novel drug delivery systems that would extend the precorneal residence time, reduce the frequency of administration and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191058/ https://www.ncbi.nlm.nih.gov/pubmed/36876464 http://dx.doi.org/10.1080/10717544.2023.2185180 |
_version_ | 1785043395920527360 |
---|---|
author | Kalaria, Vishwa J. Saisivam, S. Alshishani, Anas Aljariri Alhesan, Jameel S. Chakraborty, Sumit Rahamathulla, Mohamed |
author_facet | Kalaria, Vishwa J. Saisivam, S. Alshishani, Anas Aljariri Alhesan, Jameel S. Chakraborty, Sumit Rahamathulla, Mohamed |
author_sort | Kalaria, Vishwa J. |
collection | PubMed |
description | Traditional eye drops used for topically administering drugs have poor ocular bioavailability due to the biological barriers of the eye. There is an interest to design and develop novel drug delivery systems that would extend the precorneal residence time, reduce the frequency of administration and decrease dose-related toxicity. This study aimed to prepare Nanoparticles of Gemifloxacin Mesylate and incorporate them into an in situ gel. The nanoparticles were prepared by ionic gelation technique, using 3(2) factorial design. Sodium tripolyphosphate (STPP) was used to crosslink Chitosan. The optimized formulation of the nanoparticles (GF4) contained 0.15% Gemifloxacin Mesylate, 0.15% Chitosan and 0.20% STPP, producing 71 nm particle size and 81.11% entrapment efficiency. The prepared nanoparticles showed biphasic release, with an initial burst release of 15% in 1.0 hr and a cumulative drug release of 90.53% at the end of 24 hrs. After that, the prepared nanoparticles were incorporated into an in situ gel, using Poloxamer 407, producing a sustained drug release with efficient antimicrobial activity against gram-positive and gram-negative bacteria as confirmed by the cup plate method. |
format | Online Article Text |
id | pubmed-10191058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-101910582023-05-18 Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate Kalaria, Vishwa J. Saisivam, S. Alshishani, Anas Aljariri Alhesan, Jameel S. Chakraborty, Sumit Rahamathulla, Mohamed Drug Deliv Research Article Traditional eye drops used for topically administering drugs have poor ocular bioavailability due to the biological barriers of the eye. There is an interest to design and develop novel drug delivery systems that would extend the precorneal residence time, reduce the frequency of administration and decrease dose-related toxicity. This study aimed to prepare Nanoparticles of Gemifloxacin Mesylate and incorporate them into an in situ gel. The nanoparticles were prepared by ionic gelation technique, using 3(2) factorial design. Sodium tripolyphosphate (STPP) was used to crosslink Chitosan. The optimized formulation of the nanoparticles (GF4) contained 0.15% Gemifloxacin Mesylate, 0.15% Chitosan and 0.20% STPP, producing 71 nm particle size and 81.11% entrapment efficiency. The prepared nanoparticles showed biphasic release, with an initial burst release of 15% in 1.0 hr and a cumulative drug release of 90.53% at the end of 24 hrs. After that, the prepared nanoparticles were incorporated into an in situ gel, using Poloxamer 407, producing a sustained drug release with efficient antimicrobial activity against gram-positive and gram-negative bacteria as confirmed by the cup plate method. Taylor & Francis 2023-03-06 /pmc/articles/PMC10191058/ /pubmed/36876464 http://dx.doi.org/10.1080/10717544.2023.2185180 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Research Article Kalaria, Vishwa J. Saisivam, S. Alshishani, Anas Aljariri Alhesan, Jameel S. Chakraborty, Sumit Rahamathulla, Mohamed Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate |
title | Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate |
title_full | Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate |
title_fullStr | Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate |
title_full_unstemmed | Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate |
title_short | Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate |
title_sort | design and evaluation of in situ gel eye drops containing nanoparticles of gemifloxacin mesylate |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191058/ https://www.ncbi.nlm.nih.gov/pubmed/36876464 http://dx.doi.org/10.1080/10717544.2023.2185180 |
work_keys_str_mv | AT kalariavishwaj designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate AT saisivams designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate AT alshishanianas designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate AT aljaririalhesanjameels designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate AT chakrabortysumit designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate AT rahamathullamohamed designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate |